PLP139-151
Proteolipid protein 139-151
13 Amino Acids · MW: ~1558 Da
Amino Acids
13
Molecular Weight
~1558 Da
Half-life
minutes to hours
Research Score
4.1
Studies
91
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is PLP139-151?
A proteolipid protein epitope that reliably drives demyelinating autoimmunity in animal models. It is also used as a tolerizing antigen to map peptide-specific suppression strategies.
Key Benefits & Mechanisms
autoantigen tolerization
suppression mapping
demyelination model
Research Summary
A well-established peptide for experimental autoimmune encephalomyelitis and peptide-tolerance studies. It helps researchers evaluate whether antigen-specific exposure can shift the immune response toward regulation.
Related Peptides
P140
Phosphorylated U1-70K-derived peptide (Lupuzor)
A synthetic phosphopeptide from the spliceosomal U1-70K protein studied as an immune-tolerizing therapy for systemic lupus erythematosus. It aims to restore antigen-specific tolerance rather than broadly suppress immunity.
AutoimmunehCDR1
Human complementarity-determining region 1 peptide (Edratide)
A synthetic 19-mer derived from a human anti-DNA antibody sequence and developed as an immunomodulatory peptide for SLE. It has been studied for dampening pathogenic anti-dsDNA responses and restoring immune balance.
AutoimmunednaJP1
dnaJ heat-shock protein 70-derived peptide
A synthetic peptide derived from the bacterial dnaJ/heat-shock protein family that was evaluated as an antigen-specific therapy in rheumatoid arthritis. The concept is to induce regulatory immune responses to shared heat-shock protein epitopes.
AutoimmuneCII 259-273
Type II collagen peptide 259-273
An immunodominant collagen II epitope used in experimental and translational rheumatoid arthritis tolerance strategies. It is designed to retrain the immune system against joint-specific autoantigen rather than suppressing immunity broadly.
Autoimmune